Bruker Daltonics Announces Advanced HyStar LC/MS Software.Business/Technology Editors & Health/Medical Writers BIOWIRE2K ORLANDO, Fla.--(BW HealthWire) June 3, 2002--At the American Society for Mass Spectrometry The American Society for Mass Spectrometry is a professional association based in the United States that supports the scientific field of mass spectrometry. As of 2007, the society had approximately 7000 members primarily from the US, but also from around the world. conference, Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL) today introduces HyStar(TM) 2.3, the latest version of its hyphenation Breaking words that extend beyond the right margin. Software hyphenates words by matching them against a hyphenation dictionary or by using a built-in set of rules, or both. See discretionary hyphen. software for LC/MS LC/MS Liquid Chromatography/Mass Spectrometry and LC-NMR/MS applications. HyStar controls and integrates numerous HPLCs, UV and DAD detectors in conjunction with our life-science mass spectrometers, including ion trap, ESI-TOF and FTMS systems. HyStar FC provides UV- and MS-based fraction collection capabilities for both analytical and semi-preparative flow rates. In combination with the esquire series of ion traps, HyStar FC enables applications like UV, MS and MS/MS MS/MS Tandem Mass Spectroscopy MS/MS Multistage Mass Spectrometry based auto-purification of natural products. For proteomics applications without gels, HyStar LCn/MSn enables comprehensive two-dimensional 2D-nanoLC/MS/MS experiments using our esquire3000plus research ion trap. Digested peptides from complex protein mixtures, or even from total cell extracts can be analyzed automatically by combining two-dimensional nanoLC and autoMSn multi-dimensional mass analysis with smart precursor ion selection, as well as protein database searches via our biotools(TM) bioinformatics software. HyStar 2.3 also allows PeakParking(TM) to obtain more in-depth information from autoMSn experiments on co-eluting or very low abundance peptides. The PeakParking features boosts the success rate for identification of low abundance samples, and facilitates de novo sequencing. ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion